Kidney Tumor Program

Meet the Team

The Kidney Tumor Program, part of the Cancer and Blood Diseases Institute, is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs.

Show All

Medical Director

Hide

James I. Geller, MD Medical Director, Kidney and Liver Tumors Program 513-517-2234 james.geller@cchmc.org

High Res

James I. Geller, MD

Medical Director, Kidney and Liver Tumors Program

Co-Medical Director, Retinoblastoma Program

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-517-2234

Fax 513-636-3549

Email james.geller@cchmc.org

Show All

Clinical & Research Interests

Show

Clinical

Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology

Research

Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics

Biography

Show

James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of professor of pediatrics.

Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.

Education and Training

Show

MD: Sackler School of Medicine, 1997.

Residency: New York Medical College, 2000.

Fellowship: St Jude Children's Research Hospital, 2004.

Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.

Publications

Show

View PubMed Publications

D'Souza AM, Mark J, Demarcantonio M, Leino D, Sisson R, Geller JI. Pediatric laryngeal carcinoma in a heterozygous carrier of Fanconi anemia. Pediatr Blood Cancer. 2017 Aug;64(8).

Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, Geller JI, Ehrlich PF, Cost NG, Dome JS, Fernandez CV, Khanna G. Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group. Pediatr Radiol. 2017 Jul 8.

Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K, Dishman DJ, Backus LR, Stockman B, Brunner M, Simpson K, Spavin R, Conner J, Cripe TP. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. Clin Cancer Res. 2017 Jul 15;23(14):3566-3574.

Schaefer BA, Johnson TS, Hooper DK, Nathan JD, Geller JI. TFE3-Positive Renal Cell Carcinoma Occurring in Three Children with Dysfunctional Kidneys on Immunosuppression. Pediatr Transplant. 2017 Jun;21(4).

Geoerger B, Bourdeaut F, Dubois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN. A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients With Malignant Rhabdoid Tumor, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15;23(10):2433-2441.

Geller JI, Perentesis JP, Ahern CH, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. Pediatr Blood Cancer. 2017 Apr 27.

Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg. 2017 Apr;265(4):835-840.

Oncologists

Show

Rajaram Nagarajan, MD, MS Clinical Director, Division of Oncology 513-636-0670 rajaram.nagarajan@cchmc.org

Brian D. Weiss, MD Director, Neuroblastoma Program 513-636-9863 brian.weiss@cchmc.org

High Res

Brian D. Weiss, MD

Director, Neuroblastoma Program

Associate Director, Oncology Clinical Research

Associate Director, Safety and Compliance

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-9863

Fax 513-636-3549

Email brian.weiss@cchmc.org

Show All

Clinical Interests

Show

Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.

Biography

Show

Brian Weiss is a professor of Clinical Pediatrics in the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center. There, he specializes in benign tumors in patients with Neurofibromatosis Type 1 (NF1), and directs the Neuroblastoma Program, in addition to serving as associate director of clinical research for Oncology, and associate director for Safety and Compliance. Dr. Weiss has spearheaded efforts to reduce chemotherapy errors and leads national trials in high risk neuroblastoma, targeted radiotherapy, and targeted drugs for NF1 associated plexiform neurofibromas.

Education and Training

Show

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.

Publications

Show

View PubMed Publications